See the latest news and media coverage for BioInvent. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing antibody-based cancer therapies
bioinvent.comLast updated
In short: BioInvent planned SEK 430 million rights issue and layoffs after narrowing Q3 loss
The company plans a SEK 430 million rights issue to fund BI-1808 development. BI-1808 received FDA Fast Track designation for ovarian cancer, while financials show significant operating losses.
The firm reports robust trial outcomes for its lead immunotherapy candidates and secures FDA Fast Track status for an ovarian cancer therapy.
The FDA granted Fast Track for the anti-TNFR2 antibody in combination with pembrolizumab, after Phase 2a data showed 24% ORR and 56% DCR in platinum-resistant ovarian cancer.
BI-1206 showed 81% response rate in follicular lymphoma, and BI-1808 achieved 40% ORR in CTCL.
Lund-based Bioinvent wants to raise SEK 430 million through a new share issue. At the same time, staff cuts of up to 20 positions are planned. The stock plunges.
Research company Bioinvent decides on a large issuance equivalent to almost one-third of the company's market value.
Research company BioInvent reports increased turnover and a reduced operating loss in the third quarter compared to the corresponding period last year.
BioInvent reported updated Phase 1/2 data from Part B of its ongoing study of BI-1808 combined with pembrolizumab in heavily pretreated, platinum-resistant recurrent ovarian cancer...
Track BioInvent and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to BioInvent and other trending companies.
